Ndulue Jideofor K, Rahmatnejad Kamran, Sanvicente Carina, Wizov Sheryl S, Moster Marlene R
Wills Eye Hospital, Glaucoma Research Center, Philadelphia, PA, USA.
J Ophthalmic Vis Res. 2018 Jan-Mar;13(1):55-61. doi: 10.4103/jovr.jovr_190_17.
Cyclodestructive techniques have been a treatment option for refractory glaucoma since its first use in the 1930s. Over the past nine decades, cyclodestruction has advanced from the initial cyclodiathermy to micropulse transscleral cyclophotocoagulation (MP-TSCPC) which is the current treatment available. Complications associated with cyclodestruction including pain, hyphema, vision loss, hypotony and phthisis have led ophthalmologists to shy away from these techniques when other glaucoma treatment options are available. Recent studies have shown encouraging clinical results with fewer complications following cyclophotocoagulation, contributing greatly to the current increase in the use of cyclophotocoagulation as primary treatment for glaucoma. We performed our literature search on Google Scholar Database, Pubmed, Web of Sciences and Cochrane Library databases published prior to September 2017 using keywords relevant to cyclodestruction, cyclophotocoagulation and treatment of refractory glaucoma.
自20世纪30年代首次使用以来,睫状体破坏技术一直是难治性青光眼的一种治疗选择。在过去的九十年里,睫状体破坏术已从最初的睫状体透热疗法发展到目前可用的微脉冲经巩膜睫状体光凝术(MP-TSCPC)。与睫状体破坏相关的并发症包括疼痛、前房积血、视力丧失、低眼压和眼球痨,这使得眼科医生在有其他青光眼治疗选择时不愿采用这些技术。最近的研究表明,睫状体光凝术后并发症较少,临床结果令人鼓舞,这极大地促进了目前将睫状体光凝术作为青光眼主要治疗方法的使用增加。我们在谷歌学术数据库、PubMed、科学网和考克兰图书馆数据库中进行了文献检索,检索2017年9月之前发表的与睫状体破坏、睫状体光凝和难治性青光眼治疗相关的关键词。